Adaptimmune Therapeutics PLC

ADAPY Healthcare Biotechnology

Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.

0.03 0.00 0.00%
Market cap
$14.6M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−23.33
Beneish M
16.71
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
45.31 187.04 207.55 255.37 415.46 398.15 120.49 231.10 230.18 198.75
Total non-current assets
18.05 59.38 75.06 73.55 54.09 52.99 61.05 45.64 50.96 35.76
Total Assets
63.36 246.42 282.62 328.92 469.55 451.14 181.54 276.74 281.15 234.52
Total current liabilities
22.24 64.85 72.79 64.50 62.54 39.07 34.34 24.44 74.31 40.27
Total non-current liabilities
9.15 168.53 170.32 182.54 201.04 70.84 23.56 5.41 3.85 28.10
Total liabilities
31.39 233.38 243.10 247.04 263.59 109.92 57.91 29.85 78.16 68.37
Common Equity (Total)
31.97 13.04 39.51 81.88 205.96 341.23 123.64 246.89 202.98 166.14
Shareholders Equity (Total)
31.97 13.04 39.51 81.88 205.96 341.23 123.64 246.89 202.98 166.14
Total Debt
— 50.24 — 20.35 23.15 20.94 22.97 — — —

Show all line items

In millions of $ except per-share values · columns are period end dates